Nominated as CEO in April 2023, after joining the company as President in August 2022 and overseeing a successful AI and blockchain-based platform for patent asset management and valuation tracking.

Oversaw day-to-day executive management, operational growth, corporate strategy and enterprise relationships.

Top decision-maker in IBM’s IP business group, culminating with the Director of Patent Licensing role, where she personally generated over $150 million in revenue.

Executive role in regulatory affairs and compliance, overseeing advertising and promotional activities, as well as manufacturing and documentation quality.

Represented brand pharma companies in high-stakes Hatch-Waxman patent litigations.

Represented international brand pharma companies in high-stakes Hatch-Waxman patent litigations and related patent office proceedings, achieving notable victories for numerous clients. Counseled multiple generic pharma companies in diligence, portfolio strategy and product application development, as well as FDA and regulatory compliance.

Lead FDA Regulatory Affairs liaison, overseeing numerous e-submissions of drug applications.

Business development and FDA/regulatory affairs representative for over fifty international API suppliers Advised on IP, FDA and regulatory compliance, business and portfolio strategy, aligned with market and product development initiatives.